Ohnoshi T, Hayashi K, Ueoka H, Yamane T, Ueno K, Murashima M, Tada A, Yoshida M, Kimura I
Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 1):626-9.
Twenty-two patients with non-Hodgkin's lymphoma were treated with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP) after their disease had failed to respond to, or had relapsed after, induction chemotherapy consisting of cyclophosphamide, adriamycin, vincristine and prednisolone with/without bleomycin (CHOP/CHOP-bleo). Of 18 evaluable patients, four (22%) achieved complete remission and six (33%) responded partially. The median duration of response was 29 weeks (range, 9 to 54 weeks). The median survival time was 45 weeks for responders and 22 weeks for non-responders. Gastrointestinal toxicity was common, but well tolerated. Myelosuppression was the major dose-limiting toxicity: 11 patients (61%) experienced a febrile episode during periods of neutropenia and two patients, both of whom had massive bone marrow involvement of the disease, succumbed to infection. Despite the moderate to severe myelotoxicity, these results provide evidence that MEPP is an effective regimen for non-Hodgkin's lymphoma resistant to CHOP or CHOP-bleo.
22例非霍奇金淋巴瘤患者在接受由环磷酰胺、阿霉素、长春新碱和泼尼松龙联合/不联合博来霉素（CHOP/CHOP-博来霉素）组成的诱导化疗无效或复发后，接受了米托蒽醌、依托泊苷、顺铂和泼尼松龙的四药联合方案（MEPP）治疗。在18例可评估的患者中，4例（22%）达到完全缓解，6例（33%）部分缓解。缓解的中位持续时间为29周（范围9至54周）。缓解者的中位生存时间为45周，未缓解者为22周。胃肠道毒性很常见，但耐受性良好。骨髓抑制是主要的剂量限制性毒性：11例患者（61%）在中性粒细胞减少期间出现发热，2例患者均有大量骨髓受累，死于感染。尽管有中度至重度的骨髓毒性，但这些结果表明MEPP是一种对CHOP或CHOP-博来霉素耐药的非霍奇金淋巴瘤有效的治疗方案。
